Penumbra (PEN) Stock Faces Q3 Earnings Valuation Scrutiny
Penumbra, Inc. Reports Third Quarter 2026 Revenue of $410.1 million
Penumbra: Q3 Earnings Snapshot
Penumbra Q3 EPS $1.07 Misses $1.25 Estimate, Sales $410.145M Beat $403.345M Estimate
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results
Penumbra (PEN) Clinical Data Puts Its Valuation Back In Focus
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Penumbra Presents Results From Subset Analysis Of STORM-PE Randomized Controlled Trial At Vascular InterVentional Advances Meeting
TFX vs. PEN: Which Stock Is the Better Value Option?
TFX or PEN: Which Is the Better Value Stock Right Now?
Incuvate Files Patent Infringement Lawsuit Against Penumbra
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate
Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued
Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.